Blog Posts by Tag: Laboratory
Integrating Laboratory and Clinical Data: A Framework for Improving Reimbursement of Genomic Testing
IntroductionIn 2017, there were roughly 75,000 genetic tests on the market with about ten new tests added daily.1 The rapid expansion of genomic testing, particularly next-generation sequencing (NGS) panels, has led to uncertainty about their appropriate use, interpretation, and clinical utility. Indefinite clinical utility leads to claims denials which are appealed through a lengthy...
XIFIN’s Data Assist in Discovery of Standards Violation
With more than 3,000 payors, a siloed provider will not have the breadth and depth of data to determine if payors are adhering to standards. Because of the high volume of claims XIFIN processes and the managed services that are offered as part of our XIFIN RPM solution, our EDI services team has visibility across these payors for all of our clients. As the provider of a cloud-based revenue...
ACLA Wins in Appeals Court Versus HHS
Recently, the DC Court of Appeals determined that federal courts do in fact “have jurisdiction to decide the merits of a challenge to the federal government’s administration of the Protecting Access to Medicare Act (PAMA).”1 This ruling will result in the ACLA vs. Azar case being sent back to the DC District Court to determine if the decision from HHS/CMS to exclude hospital outreach labs from...
The Value of a Patient to Payment Process for Next-Gen Sequencing and Pharmacogenomics
The volume of next-generation sequencing (NGS) and pharmacogenomics (PGx) tests is growing every year. According to the Next Generation Sequencing Market Report published by Allied Market Research, the global NGS market is expected to reach $12.8 billion by 20221. These are high-value tests in terms of both diagnostic worth and cost. As such, laboratories need to understand the pathway to...
4 Reasons Your Lab Should Use Automated Bank Reconciliation
In a recent blog post titled “How the Most Successful Laboratories in the Country Continue to Thrive in the Midst of an Increasingly Complex Reimbursement Environment,” XIFIN Vice President of Sales, Steve Neilson discussed the importance of real-time visibility and business intelligence for laboratories. Laboratory revenue cycle management (RCM) solutions that are interoperable and are designed...
“Big Data” Can Be a Big Threat – If You’re Not Prepared to Control It
Enjoy the following content from our strategic partner, U.S. Healthtek. Imagine a day where “Big Data” isn’t some abstract concept that costs you money and resources, but is a vital component to your lab’s success as a source of revenue.Well, that day was yesterday. Competitors now understand that the abundance of data is meaningless unless you know how to manage...
Are You Taking Control of Your Lab RCM?
On July 18th in Boston, I had the opportunity to attend G2 Intelligence’s Lab Leadership Summit: Designing, Implementing & Managing a High-Profit Lab Outreach Program. This conference consisted of a variety of attendees from hospital lab directors and outreach managers, to consultants and industry partners, all connecting with the common goal of discovering how to maximize operational...
ACLA Issued a Statement to CMS on Automated Chemistry Test Panels
After claims from the Government Accountability Office (GAO) in November of 2018 that labs unbundling automated chemistry test claims will correlate to a drastic increase in Medicare spending, many industry thought leaders are responding. Most recently, ACLA has released a statement claiming that GAO’s assumptions are not backed by Medicare’s public claims data, or by ACLA’s own survey conducted...
- 1 of 4
- next ›